Verastem, Inc. (VSTM)
- Sector
- Biotechnology
- Last price
- $9.84
- As of
Kresmion compiles this page from VSTM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Verastem, Inc. (VSTM): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full VSTM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VSTM on one page. Preview it with sample data, then open it live with a free account.
Preview the VSTM dossierActive events for VSTM
- high13F: funds reduced
3 tracked funds reduced VSTM this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +106% to VSTM (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +839% to VSTM (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 96% of VSTM (2026Q2)
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 93% of VSTM (2026Q2)
FREE, NO ACCOUNT
Every event on VSTM, as it fires
You are seeing 5 of 12 events recorded on VSTM since 2026-06-05.
The five above landed across 2 days. The other 7 were recorded on 3 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VSTM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 92337C203 · 2026Q2 | $7.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 92337C203 · 2026Q2 | $1.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 92337C203 · 2026Q2 | $191K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VSTM
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VSTM mentioned in Kresmion daily briefs
VSTM against its peers
VSTM's operating margin of -550.3% ranks in the 15th percentile of 9 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | VSTM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 30.9M USD | 124M USD | 15 | 9 |
| Operating margin | -550.3% | -10.1% | 15 | 9 |
| Net margin | -677.6% | -15.1% | 15 | 9 |
| Return on equity | -366.2% | -37.6% | 10 | 14 |
Peers (17): CGEM, GLUE, JBIO, RIGL, MGTX, TBPH, CRVS, AVBP, KURA, SVRA, MLTX, PHAR, SGP, ORIC, MNKD, ARDX, INBX. Left out: IVA (period gap), AKTS (no annual filing), OBX (no annual filing), SLBT (no annual filing), ODTX (no annual filing), LTGO (no annual filing), APMD (no annual filing), CTY (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (VSTM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VSTM on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VSTM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.